Respiratory Fibrosis
Calluna Pharma AS focuses on clinical research in idiopathic pulmonary fibrosis, with interest in preserving lung function and addressing progressive fibrotic disease affecting the respiratory system.
- Idiopathic pulmonary fibrosis
- Forced vital capacity
- Lung function
The sponsor’s research activity centers on outcomes relevant to pulmonary fibrosis and the measurement of respiratory impairment in affected patients.
Pulmonary Disease Treatment
The company’s trial portfolio is directed toward treatment of chronic interstitial lung disease, with emphasis on therapeutic options for patients living with fibrotic lung disorders.
- Interstitial lung disease
- Fibrotic lung disorders
- Therapeutic efficacy
Clinical interest extends to evaluating intravenous therapy in a setting where disease progression and preservation of pulmonary capacity are central concerns.
Clinical Outcomes in Lung Health
Research activity includes assessment of respiratory endpoints used to track disease burden in idiopathic pulmonary fibrosis, particularly changes linked to breathing capacity and functional decline.
- Respiratory endpoints
- Breathing capacity
- Functional decline
This area reflects a medical focus on measurable indicators of lung performance in patients with progressive fibrotic disease.
